News
Videos
Conferences
Events
Resources
Subscribe

|Videos|June 15, 2022

Clinical Implications of the TIVO-3 Trial

Author(s)Thomas Hutson, DO, PharmD

Dr Thomas Hutson reviews the TIVO-3 trial, including the most recent data that was presented at ASCO GU.

Episodes in this series

EP. 1 Treatment Options for Patients with Renal Cell Carcinoma (RCC)

EP. 1 Treatment Options for Patients with Renal Cell Carcinoma (RCC)

EP. 2 Clinical Implications of the TIVO-3 Trial

EP. 2 Clinical Implications of the TIVO-3 Trial

EP. 3 Tivozanib: Adverse Event Profile and How Toxicities are Managed

EP. 4 Experience with Tivozanib in the 3rd Line Setting for Patients with RCC

EP. 4 Experience with Tivozanib in the 3rd Line Setting for Patients with RCC

EP. 5 Future Perspectives in Renal Cell Carcinoma (RCC)

EP. 5 Future Perspectives in Renal Cell Carcinoma (RCC)

Newsletter

Stay up to date on cancer updates, research and education

Related Content

The Future of CLL Care: Medical Breakthroughs and Patient-Physician Collaboration

September 20th 2024

Living Well With CLL: Nutrition, Exercise, and Lifestyle Tips From Patients and Doctors

September 20th 2024

Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs

September 13th 2024

CLL Treatment and Quality of Life: Patient Empowerment and Shared Decision-making

September 13th 2024

LL Treatment Roadmap: Navigating First-Line Options With Your Doctor

September 6th 2024

Trending on CURE

FDA Approves Enhertu Plus Perjeta in Advanced HER2+ Breast Cancer

Acupuncture Improves Cognitive Function in Breast Cancer Survivors

Light the Night and Survivorship: The Importance of Remembrance

FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer

Accepting That You Are Changed by Cancer

© 2025 MJH Life Sciences^®

All rights reserved.